14th Annual World ADC San Diego

Robust Tumor Organoid Screening to Accelerate Discovery of Antibody-Drug Conjugates

• Over 600 commercially qualified tumor organoid models characterized by the Tempus xT comprehensive NGS test that can be used in standardized or custom drug screens
• A pan-cancer organoid panel, Pan60™, consisting of sixty predefined primary and metastatic tumor organoids for targeted drug screens across nine indications, is ideal for screening ADC targets
• Model ADC responses across a broad range of experimental scenarios, including free-payload and isotype control normalization, custom dose curve assessments, and optimized time intervals